IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 202 filers reported holding IMPAX LABORATORIES INC in Q4 2017. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $5,090,000 | +158.6% | 250,724 | +105.1% | 0.10% | +135.7% |
| Q2 2017 | $1,968,000 | -14.8% | 122,265 | -33.1% | 0.04% | -10.6% |
| Q1 2017 | $2,311,000 | -5.7% | 182,715 | -1.2% | 0.05% | 0.0% |
| Q4 2016 | $2,451,000 | -53.0% | 185,015 | -15.8% | 0.05% | -49.5% |
| Q3 2016 | $5,210,000 | +149.2% | 219,830 | +215.3% | 0.09% | +165.7% |
| Q2 2014 | $2,091,000 | +252.0% | 69,721 | +209.9% | 0.04% | +250.0% |
| Q1 2014 | $594,000 | -77.5% | 22,501 | -78.6% | 0.01% | -75.0% |
| Q4 2013 | $2,642,000 | +170.1% | 105,109 | +119.9% | 0.04% | +135.3% |
| Q3 2013 | $978,000 | – | 47,799 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 423,161 | $13,406,000 | 7.47% |
| Aravt Global | 2,300,000 | $72,864,000 | 5.43% |
| Slate Path Capital LP | 2,330,000 | $73,814,000 | 5.16% |
| Orbimed Advisors | 6,678,000 | $211,559,000 | 2.02% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Penn Capital Management Company, LLC | 709,045 | $22,463,000 | 0.94% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $7,920,000 | 0.79% |
| NEW AMSTERDAM PARTNERS LLC/NY | 276,169 | $8,749,000 | 0.76% |
| Matarin Capital Management, LLC | 52,932 | $1,676,886,000 | 0.74% |